Log in or Sign up for Free to view tailored content for your specialty!
Lymphoma News
Dupilumab treatment for atopic dermatitis linked to cutaneous T-cell lymphoma development
A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.
Regimen improves OS in diffuse large B-cell lymphoma
The addition of glofitamab-gxbm to gemcitabine and oxaliplatin improved OS among patients with relapsed or refractory diffuse large B-cell lymphoma compared with rituximab, gemcitabine and oxaliplatin, according to the agent’s manufacturer.
Log in or Sign up for Free to view tailored content for your specialty!
Value of MRI, lumbar puncture questioned for immune cell-associated neurotoxicity syndrome
MRIs and lumbar punctures may not provide enough therapeutic value to be standard-of-care diagnostic tests in patients suffering neurologic symptoms following chimeric antigen receptor T-cell therapy.
Enalapril does not prevent chemotherapy-related heart damage in breast cancer, lymphoma
ATLANTA — Enalapril plus standard care was not superior to standard care alone for preventing cardiotoxicity in patients receiving treatment for breast cancer or lymphoma, according to new data from the PROACT trial.
Parents of children with cancer more often seek help for anxiety, depression
Parents of children with cancer made mental health visits, including those for anxiety and depression, significantly more often than other parents, according to results published in JAMA Network Open.
‘Wake-up call’: Cardiovascular toxicity a concern for patients receiving bispecifics
More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.
Most U.S. cancer trials conducted in more affluent, less diverse areas
Most of the major cancer clinical trial centers in the U.S. are located near more affluent and white populations compared with the national average, according to results published in JAMA Oncology.
FDA approves Breyanzi CAR-T for chronic lymphocytic leukemia, small lymphocytic lymphoma
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Risk factors identified for secondary leukemia in patients who received CAR T cells
Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.
Those with blood cancers ‘can’t rely on vaccination’ for protection from severe COVID-19
Regardless of vaccination status, individuals with hematologic malignancies had increased odds of developing severe COVID-19 until oral antivirals became widely available in mid-2022, according to data published in JAMA Network Open.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read